The European Hematology Association (EHA)

At the 2024 European Hematology Association Annual Congress, researchers presented the multilineage and safety results from the COMMANDS trial of transfusion-dependent, erythropoiesis-stimulating agent–naïve patients with very low-, low-, or intermediate-risk myelodysplastic syndromes. Read More ›

At the European Hematology Association 2024 Annual Conference, researchers analyzed the relationship between hemoglobin and the quality of life of transfusion-dependent patients with lower-risk myelodysplastic syndromes receiving luspatercept or epoetin alfa. Read More ›

At the European Hematology Association 2024 Annual Conference, researchers presented the real-world dose escalation of luspatercept and its outcomes among patients with lower-risk myelodysplastic syndromes. Read More ›

At the European Hematology Association 2024 Annual Conference, researchers explored the emotional, physical, and financial burden experienced by patients with transfusion-dependent lower-risk myelodysplastic syndromes based in North America and Europe. Read More ›

Researchers presented a model to compare treatment outcomes for patients with lower-risk myelodysplastic syndromes who rely on red blood cell transfusions starting from first-line treatment initiation throughout their lifetime. Read More ›

Induction with ixazomib, daratumumab, and low-dose dexamethasone in frail elderly newly diagnosed multiple myeloma patients in the HOVON 143 study was meaningfully effective regarding ORR and PFS, but with continued toxicity concerns. Read More ›

Melflufen/dexamethasone demonstrated meaningful activity and manageable safety profile in patients with relapsed/refractory multiple myeloma who had ≥2 prior lines of therapy and were also refractory to pomalidomide and/or an anti-CD38 monoclonal antibody. Read More ›

In the DREAMM-2 study of belantamab mafodotin in heavily pretreated relapsed/refractory multiple myeloma patients, comparable overall response rates (~30%) were observed between patients who had 3 to 6 prior therapies and those with ≥7. Read More ›

Addition of venetoclax to bortezomib/dexamethasone in relapsed/refractory multiple myeloma patients (BELLINI phase 3 study) improves progression-free survival, but also results in higher mortality, with t(11;14) or BCL2^high gene expression patients benefiting most. Read More ›

In patients with multiple myeloma who undergo frontline optimized induction followed by ASCT, MRD assessment and clinical response time kinetics were predictive of unsustained complete remission, based on a subgroup analysis of PETHEMA/GEM2012MENOS65. Read More ›